1. Home
  2. SEAT vs MLYS Comparison

SEAT vs MLYS Comparison

Compare SEAT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEAT
  • MLYS
  • Stock Information
  • Founded
  • SEAT 2001
  • MLYS 2019
  • Country
  • SEAT United States
  • MLYS United States
  • Employees
  • SEAT N/A
  • MLYS N/A
  • Industry
  • SEAT Industrial Machinery/Components
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SEAT Industrials
  • MLYS Health Care
  • Exchange
  • SEAT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • SEAT 366.2M
  • MLYS 1.0B
  • IPO Year
  • SEAT N/A
  • MLYS 2023
  • Fundamental
  • Price
  • SEAT $1.63
  • MLYS $13.84
  • Analyst Decision
  • SEAT Buy
  • MLYS Strong Buy
  • Analyst Count
  • SEAT 11
  • MLYS 4
  • Target Price
  • SEAT $4.49
  • MLYS $27.00
  • AVG Volume (30 Days)
  • SEAT 1.4M
  • MLYS 827.2K
  • Earning Date
  • SEAT 08-05-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • SEAT N/A
  • MLYS N/A
  • EPS Growth
  • SEAT N/A
  • MLYS N/A
  • EPS
  • SEAT N/A
  • MLYS N/A
  • Revenue
  • SEAT $748,757,000.00
  • MLYS N/A
  • Revenue This Year
  • SEAT N/A
  • MLYS N/A
  • Revenue Next Year
  • SEAT $4.42
  • MLYS N/A
  • P/E Ratio
  • SEAT N/A
  • MLYS N/A
  • Revenue Growth
  • SEAT 0.82
  • MLYS N/A
  • 52 Week Low
  • SEAT $1.44
  • MLYS $8.24
  • 52 Week High
  • SEAT $5.78
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • SEAT 37.49
  • MLYS 42.26
  • Support Level
  • SEAT $1.60
  • MLYS $12.95
  • Resistance Level
  • SEAT $1.97
  • MLYS $14.09
  • Average True Range (ATR)
  • SEAT 0.11
  • MLYS 0.77
  • MACD
  • SEAT 0.01
  • MLYS -0.14
  • Stochastic Oscillator
  • SEAT 6.76
  • MLYS 28.24

About SEAT Vivid Seats Inc.

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: